Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jan 24, 2012
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
Respiratory distress is a common reason for admission to the neonatal intensive care unit (NICU) for both preterm and full term newborns. TTN and RDS are the two most common diagnoses associated with respiratory distress. Due to their similar clinical presentations, it is often difficult to differentiate the two diseases clinically. Currently chest radiography is used to differentiate between TTN and RDS, however, radiographic findings are not always definitively diagnostic.
In preliminary studies, lung ultrasonography has been shown to be a useful tool in diagnosing both TTN and RDS. Howe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • gestational age ≥ 28 weeks
- * symptoms of respiratory distress defined as:
- • tachypnea (respiratory rate \> 60 breaths per minute)
- • FiO2 requirement \>21%
- • intercostal/subcostal retractions
- • grunting and/or nasal flaring
- • If clinically warranted, a chest x-ray will be done as part of the workup for respiratory distress; these patients with CXR will be included in the study.
- • Inclusion criteria for the control group will be gestational age ≥ 28 weeks with no symptoms of respiratory distress (defined above).
- Exclusion Criteria:
- • neonates with prenatally diagnosed structural cardiac disease
- • major multiple congenital anomalies
- • other causes of respiratory distress that are not RDS or TTN (e.g. pneumothorax, CCAM or pneumonia).
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Ian Holzman, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials